|Articles|June 5, 2013
From ASCO: Updates in HER2-positive breast cancers
Author(s)Debu Tripathy
Advertisement
Debu Tripathy, MD, editor-in-chief of CURE, discusses preliminary studies on combining Herceptin (trastuzumab) with existing drugs to treat HER2-positive breast cancer. These highlighted studies were presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Trodelvy Plus Keytruda Shows Lasting Benefit in Metastatic Breast Cancer
2
Medical Cannabis Education Improves Oncology Nurses’ Confidence in Patient Discussions
3
Oncologist Answers Most Asked Questions About Colorectal Cancer
4
Nurse-Led Quality Initiative Reduces CLABSI Risk in Hematologic Cancer Care
5